Selection Strategy: Specificity vs. Universality
Pharmacotherapy for ventricular arrhythmias requires a precise understanding of the clinical objective. Clinicians must constantly choose between broad-spectrum and specific agents. While some drugs serve as universal tools, narrow-spectrum agents are preferred for isolated ventricular premature beats.
Classically, the specific ventricular antiarrhythmics belong to Class IB according to the Vaughan-Williams classification. This group includes such drugs as lidocaine, mexiletine, and phenytoin. Their use is justified precisely when targeted action exclusively on ventricular rhythm disorders is required without unnecessary interference with other components of the cardiac conduction system.
Amiodarone: Polyvalent Mechanism and Universality
Amiodarone differs fundamentally from specific Class IB drugs. It is a powerful universal antiarrhythmic agent whose high efficacy is due to its polyvalent mechanism of action.
The primary pharmacological effect is based on the blockade of potassium channels in cardiomyocyte membranes. This targeted action leads to a significant increase in the effective refractory period (ERP), which prevents premature cell depolarization.
However, amiodarone's uniqueness lies in its additional effects. It is capable of blocking:
- Sodium channels.
- Calcium channels.
- $\beta$-adrenergic receptors.
This comprehensive profile allows it to be used in a wide variety of pathologies: it terminates both ventricular and supraventricular arrhythmias with equal effectiveness. Furthermore, the drug possesses significant antianginal properties, making it successful in combination therapy for angina pectoris.
Toxicity Profile of Amiodarone
Amiodarone's broad spectrum of action is inevitably associated with the risk of specific side effects that require careful clinical monitoring. All adverse reactions can be divided into two broad categories: cardiac and extracardiac.
Cardiac complications include direct suppression of sinus node function, manifesting as marked bradycardia, as well as slowed impulse conduction leading to impaired atrioventricular (AV) conduction.
Extracardiac effects are equally significant and specific. The drug actively interferes with hormone metabolism, which can trigger thyroid dysfunction—patients develop either hypothyroidism or hyperthyroidism. Another characteristic marker of toxicity is ophthalmological: microcrystals of the active substance frequently deposit in the corneal epithelium, a phenomenon known in clinical practice as corneal microdeposits.
Phenytoin: Unique Hemodynamic Profile
Phenytoin (also known as diphenylhydantoin) occupies a special place among antiarrhythmic drugs. Originally developed and used exclusively as an anticonvulsant, its ability to combine anticonvulsant and prominent antiarrhythmic activity was later demonstrated.
The main clinical advantage of phenytoin is its exceptional hemodynamic safety. Unlike the vast majority of other antiarrhythmic drugs, phenytoin:
- Does not significantly depress myocardial contractility (preserving the heart's pumping function).
- Does not cause significant blood pressure reduction.
Due to these unique properties, phenytoin is recognized as the gold standard and first-line drug for treating severe arrhythmias triggered by digitalis toxicity (cardiac glycoside overdose).